The genetic landscape and possible therapeutics of neurofibromatosis type 2.

Ghalavand, Mohammad Amin; Asghari, Alimohamad; Farhadi, Mohammad; Taghizadeh-Hesary, Farzad; Garshasbi, Masoud; Falah, Masoumeh

Ghalavand, Mohammad Amin; Asghari, Alimohamad; Farhadi, Mohammad; Taghizadeh-Hesary, Farzad; Garshasbi, Masoud; Falah, Masoumeh.

Afiliación

Ghalavand MA; ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Asghari A; Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Farhadi M; ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Taghizadeh-Hesary F; Skull Base Research Center, The Five Senses Health Institute, Hazrat Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Garshasbi M; ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Falah M; ENT and Head and Neck Research Center and Department, The Five Senses Health Institute, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Cancer Cell Int ; 23(1): 99, 2023 May 23.

Article en En | MEDLINE | ID: mdl-37217995

Palabras clave

Acoustic neuroma; Hearing loss; Meningiomas; Merlin; Molecular targeted therapy; NF2; Neurofibromatosis type 2; Vestibular schwannoma

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Cell Int Año: 2023 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google